NeoNeuro
Created in 2015
- BETA
To investigate (B)
Some signals may appear as inconsistent with a regular activity Social networks
599Activities
Technologies
Entity types
Location
38 Rue de Berri, 75008 Paris, France
Paris
France
Employees
Scale: 2-10
Estimated: 2
SIREN
811689017Engaged corporates
1
1 0Added in Motherbase
1 year, 2 months ago
biotech Value proposition
APTAMARKERS: Diagnostic fingerprints in blood for pathology detection
NeoNeuro has developed a new scientific approach named Aptamarkers. In the past, biomarkers for the diagnosis of diseases have been developed based on an understanding of the disease and the effect of the disease on the regulation of proteins or metabolites. This approach is time-consuming and expensive as experimental hypothesis regarding the pathophysiology of the disease must be tested and progressively built upon.
NeoNeuro set out to develop a new platform with the capacity to screen all epitopes that are present in blood. We are not only screening all molecules in blood (proteins, metabolites and oligonucleotides, including non-coding RNA) but we are also screening for changes in the conformation or complexes among these molecules. This breakthrough is achieved through the use of enriched aptamer libraries. Aptamers are single stranded oligonucleotides that mimic antibodies in their ability to bind to target molecules.
The Aptamarker platform enables the first truly deep data discovery of biomarkers in any biological fluid. The aptamers are themselves biomarkers, their quantity following a round of selection is directly used to diagnose disease states.
The vision of NeoNeuro is to improve healthcare by providing deep analysis of blood on an individual basis. Our ultimate goal is to be able to quantify all molecular species in a blood sample at a cost and speed that enables comprehensive monitoring of health at an unprecedented level.
biotechnology, Alzheimer's, biomarkers, blood diagnosis, pathology detection, and aptamersOriginal language
APTAMARKERS: Diagnostic fingerprints in blood for pathology detection
NeoNeuro has developed a new scientific approach named Aptamarkers. In the past, biomarkers for the diagnosis of diseases have been developed based on an understanding of the disease and the effect of the disease on the regulation of proteins or metabolites. This approach is time-consuming and expensive as experimental hypothesis regarding the pathophysiology of the disease must be tested and progressively built upon.
NeoNeuro set out to develop a new platform with the capacity to screen all epitopes that are present in blood. We are not only screening all molecules in blood (proteins, metabolites and oligonucleotides, including non-coding RNA) but we are also screening for changes in the conformation or complexes among these molecules. This breakthrough is achieved through the use of enriched aptamer libraries. Aptamers are single stranded oligonucleotides that mimic antibodies in their ability to bind to target molecules.
The Aptamarker platform enables the first truly deep data discovery of biomarkers in any biological fluid. The aptamers are themselves biomarkers, their quantity following a round of selection is directly used to diagnose disease states.
The vision of NeoNeuro is to improve healthcare by providing deep analysis of blood on an individual basis. Our ultimate goal is to be able to quantify all molecular species in a blood sample at a cost and speed that enables comprehensive monitoring of health at an unprecedented level.
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Other 8 Dec 2022 | | |